Loading...
SYRS logo

Syros Pharmaceuticals, Inc.Informe acción OTCPK:SYRS

Capitalización bursátil US$10.7k
Precio de las acciones
US$0.0002
Mi valor justo
No disponible
1Y-99.3%
7D0%
1D
Valor de la cartera
​
Ver

Syros Pharmaceuticals, Inc.

Informe acción OTCPK:SYRS

Capitalización de mercado: US$10.7k

Syros Pharmaceuticals (SYRS) Resumen de Acciones

Syros Pharmaceuticals, Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos para neoplasias hematológicas. Saber más

Análisis fundamental de SYRS
Puntuación del snowflake
Valoración0/6
Crecimiento futuro0/6
Rendimiento pasado0/6
Salud financiera0/6
Dividendos0/6

Análisis de riesgos

Los últimos informes financieros tienen más de un año

No tiene una capitalización de mercado significativa ($11K)

Precio de las acciones muy volátil durante los últimos 3 meses en comparación con el mercado US


SYRS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Competidores de Syros Pharmaceuticals, Inc.

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Syros Pharmaceuticals
Precios históricos de las acciones
Precio actual de la acciónUS$0.0002
Máximo en las últimas 52 semanasUS$0.04
Mínimo de 52 semanasUS$0.000001
Beta0
Cambio en 1 mes0%
Variación en 3 meses0%
Cambio de 1 año-99.28%
Variación en 3 años-99.90%
Variación en 5 años-99.90%
Variación desde la OPV-99.90%

Noticias y actualizaciones recientes

Recent updates

Seeking Alpha • Jul 02

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

Summary Syros Pharmaceuticals focuses on developing therapies for myeloid cancers. The main pipeline candidate is tamibarotene, with positive signals in phase 2 trial and a key data readout coming in Q4 2024. Financially, SYRS has $112.2 million in assets, but faces a high cash burn rate and potential need for more financing. Read the full article on Seeking Alpha
Seeking Alpha • Jan 14

Syros Pharmaceuticals: Rising Despite Dilution, A Must Look

Summary Syros Pharmaceuticals is a cancer-focused biotech working on therapies for blood cancer, with a main drug in development. The company's main program is tamibarotene, targeting specific myeloid cancers with high RARA gene expression. Syros has encouraging data from a phase 2 trial and is currently conducting a phase 3 trial, but lack of asset diversification and high risk should be considered. Read the full article on Seeking Alpha
Seeking Alpha • Sep 20

Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders

Summary Syros Pharmaceuticals has recently acquired its peer Tyme Technologies. The sole purpose of the merger was to acquire TYME's cash balance. Concurrently with the merger, the largest shareholders put in an additional $130m into the company at over 30% premium to current prices. This strong vote of confidence from insiders makes SYRS very interesting, especially when shares are below insiders' entry price. SYRS share price has just declined by 17%, presenting an attractive entry point. SYRS now trades materially below net cash while being fully funded to bring development programs to fruition. The merger between Syros Pharmaceuticals (SYRS) and Tyme Technologies (TYME) was announced in the beginning of July and closed last Friday. This opportunity attracted our interest purely from the merger arb perspective but it actually had two angles to it (with the second one being the key point of this article): Pure merger arbitrage play - pretty much till the closing the spread on the merger stood at 20-40% (chart below) and we could not see any real risks in this transaction despite our best efforts to dig something out. Although such a wide spread on a merger with limited risks might seem too-good-to-true, we actually spot similar opportunities quite often in the less analyzed microcap space and cover them on our premium service Special Situation Investing. The merger arb aspect of the transaction has now fully played out, but there is another angle to the story. Another angle of TYME / SYRS transaction is that SYRS is a very well-positioned pharma company with an attractive development portfolio and this merger simply was an opportunity to acquire SYRS at 20-30% discount to the prevailing market prices by buying it through TYME. Now that the merger closed, one can no longer acquire TYME stock with hopes it will convert to SYRS, but luckily enough SYRS is now itself trading materially below the levels of the merger announcement, presenting an equally attractive opportunity as was acquiring it through TYME. Why the wide spread on the merger? Note: You can easily skip to the next section as this one only looks at a strange market inefficiency in these types of situations. TYME/SYRS Merger Spread Despite our attempts to find an explanation for this wide 20-40% spread, we could not find anything. So in the end we concluded that this is one of those micro-cap merger arbitrage situations where the market is simply not paying attention and our research actually gives us an edge. We love these types of opportunities and covered these regularly on Special Situation Investing. The spread on SYRS / TYME merger seemed completely overblown given the short expected closing timeline, persistently cheap SYRS hedging fees and very low risk of merger termination. The merger was basically an equity raise for SYRS. The buyer openly stated that it was interested solely in TYME's net cash position ($60m) to enhance its liquidity and indicated that TYME's existing drug development program will be put on hold. Shareholder approvals seemed guaranteed as around 35% of SYRS and 30% of TYME shares had already been in support. The PIPE financing for an additional $130m from the largest shareholders at a premium to the market prices added further confidence that every single party of the transaction wants this to close successfully. As expected, shareholder approvals were received on the 15th of September and the merger closed a day later. As further proof of market inefficiency in these types of situations, the spread still persisted even after the shareholder approval. After the vote SYRS issued an announcement stating that the merger will close the next day but the spread persisted and even increased slightly to 10%. Only by the end of the day the spread was finally eliminated. What's next for SYRS? Note: post-merger closing, SYRS has effected a 10-to-1 reverse stock split. Further calculations refer to SYRS's share price and count after the split. Aside from raising cash through the merger with TYME, SYRS also simultaneously did a huge $130m PIPE (vs $50m market cap at the time) at $0.94/share ($9.40/share adjusted for the recent split). The participants were mostly major shareholders of the company - large and reputable PE firms including Bain Capital, Invus Public Equities, Ally Bridge MedAlpha, and others. SYRS co-founder and founding investor Flagship Pioneering also participated. The fact that these firms, who have significantly more knowledge and information about the SYRS pipeline have put that much money at over 30% premium to current prices adds significant confidence in the value of the company's current pipeline. It's no secret that biopharma investing is largely a gamble. However, one thing for sure is that such reputable firms do not like throwing good money after the bad, and especially not in this size. Both transactions have now provided SYRS with enough cash runway through 2025. Post-merger, SYRS has 27.9m of outstanding shares and total cash of ~$240m (after deducting transaction expenses). Net cash is at ~$200m or ~$7.16 per SYRS share. SYRS is down 17% on the first day after the merger close and now sits close to an all-time-low at $6.08/share. The stock is currently trading 15% below net cash and over 35% discount to where the largest shareholders have just made a material investment. SYRS Net Cash Before the merger, SYRS used to trade at up to 8-10% discount to net cash. However, right now the company is in much better shape - a very strong cash position and no financing/dilution risk until 2026 - should be enough to advance its main treatment Tamibarotene into commercialization. If Tamibarotene shows good phase 3 results, the upside from current levels will be very material. These points, as well as the recent vote of confidence from major shareholders, suggest that 15% discount to net cash is overly punitive.
Seeking Alpha • Sep 13

Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609

Syros Pharmaceuticals (NASDAQ:SYRS) on Tuesday said the U.S. FDA had granted an orphan drug designation to its inhibitor SY-5609 for the treatment of pancreatic cancer. SY-5609 is currently being assessed in combination with chemotherapy for the treatment of patients with relapsed metastatic pancreatic cancer, SYRS said in a statement. The FDA's orphan drug designation program expedites the development and evaluation of a drug or biological product to prevent a rare disease or condition. SYRS stock +4.5% to $0.80 after hours.
Seeking Alpha • Aug 08

Syros Pharmaceuticals Q2 2022 Earnings Preview

Syros Pharmaceuticals (NASDAQ:SYRS) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.41 (-13.9% Y/Y) and the consensus Revenue Estimate is $4.78M (-7.4% Y/Y). Over the last 1 year, SYRS has beaten EPS estimates 50% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 3 upward revisions and 0 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

Rentabilidad de los accionistas

SYRSUS BiotechsMercado US
7D0%2.9%2.5%
1Y-99.3%33.0%26.4%

Rentabilidad vs. Industria: Los resultados de SYRS fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 33% el año pasado.

Rentabilidad vs. Mercado: SYRS obtuvo unos resultados inferiores a los del mercado US, que fueron del 26.4% el año pasado.

Volatilidad de los precios

Is SYRS's price volatile compared to industry and market?
SYRS volatility
SYRS Average Weekly Movement158.9%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Precio estable de las acciones: El precio de las acciones de SYRS ha sido volátil durante los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de SYRS ha disminuido de 842% a 159% en el último año, pero sigue siendo superior al 75% de los valores de US.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
2011n/an/awww.syros.com

Syros Pharmaceuticals, Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos para neoplasias hematológicas. Los principales productos candidatos de la empresa son el tamibaroteno, un agonista selectivo del receptor alfa del ácido retinoico, que está en fase III de ensayo clínico para un subconjunto genómicamente definido de pacientes con síndrome mielodisplásico y en fase II de ensayo clínico para pacientes con leucemia mieloide aguda; SY-2101, una nueva forma oral de trióxido de arsénico para el tratamiento de pacientes con leucemia promielocítica aguda; y SY-5609, un inhibidor de la cinasa 7 dependiente de ciclina, que se encuentra en un ensayo clínico de fase I en pacientes con tumores sólidos avanzados seleccionados. La empresa se conocía anteriormente como LS22, Inc. y cambió su nombre por el de Syros Pharmaceuticals, Inc. en agosto de 2012.

Resumen de fundamentos de Syros Pharmaceuticals, Inc.

¿Cómo se comparan los beneficios e ingresos de Syros Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de SYRS
Capitalización bursátilUS$10.73k
Beneficios(TTM)-US$97.81m
Ingresos (TTM)US$386.00k
0.0x
Ratio precio-ventas (PS)
0.0x
Ratio precio-beneficio (PE)

¿Está SYRS sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de SYRS
IngresosUS$386.00k
Coste de los ingresosUS$88.64m
Beneficio bruto-US$88.25m
Otros gastosUS$9.56m
Beneficios-US$97.81m

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)0
Margen bruto0.00%
Margen de beneficio neto0.00%
Ratio deuda/patrimonio0.0%

¿Cómo se ha desempeñado SYRS a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/26 21:15
Precio de las acciones al final del día2026/05/26 00:00
Beneficios2024/09/30
Ingresos anuales2023/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Syros Pharmaceuticals, Inc. está cubierta por 4 analistas. 0 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Mark BreidenbachOppenheimer & Co. Inc.
Zegbeh JallahRoth Capital Partners
Philip NadeauTD Cowen